Vivitra is a brand name for Trastuzumab, a humanized monoclonal antibody used to treat certain types of breast cancer and gastric cancer.
Composition:
Each 150mg vial of Vivitra 150mg contains trastuzumab, a recombinant humanized monoclonal antibody, and sodium chloride.
Mechanism of Action: Trastuzumab is a targeted therapy that works by binding to the human epidermal growth factor receptor 2 (HER2) protein on the surface of breast cancer cells. This binding prevents the HER2 protein from sending growth signals to the cells, ultimately leading to cell death and tumor shrinkage.
Use: Vivitra is used to treat:
- HER2-positive breast cancer, in combination with chemotherapy (such as doxorubicin, cyclophosphamide, and methotrexate) as adjuvant treatment after surgery.
- HER2-positive metastatic breast cancer, in combination with paclitaxel or docetaxel as first-line treatment.
- HER2-positive metastatic breast cancer, in combination with chemotherapy (such as docetaxel, carboplatin, and trastuzumab) as first-line treatment.
- HER2-positive gastric cancer, in combination with chemotherapy (such as cisplatin and capecitabine) as first-line treatment.
Dosage: The recommended dosage of Vivitra is:
- Adjuvant treatment: 8 mg/kg every 3 weeks for 12 cycles.
- Metastatic breast cancer: 8 mg/kg every 3 weeks.
- Gastric cancer: 8 mg/kg every 3 weeks.
Side Effects: Common side effects of Vivitra include:
- Fatigue
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
- Flu-like symptoms
Recommendation: Vivitra should be administered under the guidance of an experienced healthcare provider. Patients should be monitored for signs of cardiac toxicity, including congestive heart failure, and patients with a history of cardiac disease may be at increased risk.
Important Note: Vivitra is not recommended for use in patients with a history of allergic reactions to trastuzumab or other ingredients in the product. Patients should be advised to report any changes in their heart rate or blood pressure to their healthcare provider immediately.
Reviews
There are no reviews yet.